Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial
吸入式双特异性单域抗体 BM219 用于治疗轻度至中度 COVID-19:一项双盲、随机、安慰剂对照的 II 期试验
期刊:Cell Discovery
影响因子:12.5
doi:10.1038/s41421-025-00813-0
Wu, Yanling; Li, Yuan; Zhang, Ping; Guo, Siwei; Yuan, Fang; Liu, Vivian; Yu, Ting; Lin, Feng; Yang, Nan; Tu, Chao; Lu, Hongzhou; Ying, Tianlei; Li, Xin